Next Article in Journal
Caffeine and Gastric Emptying Time in Very Preterm Neonates
Next Article in Special Issue
Lipoprotein(a) Lowering—From Lipoprotein Apheresis to Antisense Oligonucleotide Approach
Previous Article in Journal
Identification of a miRNA Based-Signature Associated with Acute Coronary Syndrome: Evidence from the FLORINF Study
Open AccessArticle

Age-Dependent Efficacy of Ezetimibe for Low-Density Lipoprotein Cholesterol Reduction in Japanese Patients with or without Type 2 Diabetes Mellitus

1
Department of Diabetes, Endocrinology and Metabolism, School of Medicine, Fukushima Medical University, 1 Hikarigaoka, Fukushima 960-1247, Japan
2
Department of Cardiology, Nakagami Hospital, 610 Noborikawa, Okinawa 904-2195, Japan
3
Department of Cardiology, Tomishiro Central Hospital, 25 Ueta, Tomishiro, Okinawa 901-0243, Japan
4
Department of Diabetes and Life-Style Related Disease Center, Tomishiro Central Hospital, 25 Ueta, Tomishiro, Okinawa 901-0243, Japan
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2020, 9(6), 1675; https://doi.org/10.3390/jcm9061675
Received: 3 May 2020 / Revised: 28 May 2020 / Accepted: 29 May 2020 / Published: 1 June 2020
Ezetimibe reduces cardiovascular risk by lowering the levels of low-density lipoprotein cholesterol (LDL-C). However, there is limited information regarding the factors associated with ezetimibe-mediated LDL-C reduction. We investigated the factors associated with LDL-C reduction after ezetimibe administration in Japanese patients with or without type 2 diabetes mellitus (T2DM). This single-center retrospective observational study enrolled a total of 266 consecutive ezetimibe-naïve patients, of which 154 were excluded because of either switching from statin or fenofibrate to ezetimibe (n = 52) or ezetimibe discontinuation (n = 102). Finally, 112 patients were eligible for analysis. To identify the factors influencing LDL-C levels, univariate and multivariate linear regression analyses were performed after 52 weeks of ezetimibe treatment. Overall, advanced age, T2DM, and high baseline LDL-C were significantly associated with a greater decrease in LDL-C levels. In the non-T2DM group, advanced age and high baseline LDL-C were associated with greater decrease in LDL-C levels. In the T2DM group, baseline LDL-C was the only factor that influenced the change in LDL-C levels. Advanced age was significantly associated with higher LDL-C reduction in non-T2DM patients, but not in T2DM patients. Ezetimibe use might be beneficial in older patients without T2DM. The lack of association between age and the LDL-C lowering effect by ezetimibe in patients with T2DM may be due to yet unknown mechanism except low statistical power. View Full-Text
Keywords: ezetimibe; low-density lipoprotein cholesterol; age ezetimibe; low-density lipoprotein cholesterol; age
Show Figures

Figure 1

MDPI and ACS Style

Yamaguchi, S.; Oba, K.; Higa, M.; Arasaki, O.; Shimabukuro, M. Age-Dependent Efficacy of Ezetimibe for Low-Density Lipoprotein Cholesterol Reduction in Japanese Patients with or without Type 2 Diabetes Mellitus. J. Clin. Med. 2020, 9, 1675.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop